WuXi Biologics (Cayman)
(OTC) WXIBF
WuXi Biologics (Cayman) Financials at a Glance
Market Cap
$19.03B
Revenue (TTM)
$40.27B
Net Income (TTM)
$8.22B
EPS (TTM)
$0.16
P/E Ratio
27.12
Dividend
$0.00
Beta (Volatility)
0.43 (Low)
Dividend
$0.00
Beta (Volatility)
0.43 (Low)
Price
$4.60
Volume
273
Open
$4.60
Price
$4.60
Volume
273
Open
$4.60
Previous Close
$4.60
Daily Range
$4.60 - $4.60
52-Week Range
$2.74 - $5.61
Dividend
$0.00
Beta (Volatility)
0.43 (Low)
Price
$4.60
Volume
273
Open
$4.60
Previous Close
$4.60
Daily Range
$4.60 - $4.60
52-Week Range
$2.74 - $5.61
WXIBF News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout WuXi Biologics (Cayman)
Industry
Life Sciences Tools and Services
Sector
Health CareEmployees
12,575
CEO
Zhi Sheng Chen, PhD
Website
www.wuxibiologics.comHeadquarters
Wuxi, 214092, CN
WXIBF Financials
Key Financial Metrics (TTM)
Gross Margin
46%
Operating Margin
30%
Net Income Margin
23%
Return on Equity
11%
Return on Capital
12%
Return on Assets
8%
Earnings Yield
3.69%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$19.03B
Shares Outstanding
4.14B
Volume
273
Short Interest
0.00%
Avg. Volume
10.15K
Financials (TTM)
Gross Profit
$9.76B
Operating Income
$6.47B
EBITDA
$8.17B
Operating Cash Flow
$5.22B
Capital Expenditure
$3.93B
Free Cash Flow
$1.29B
Cash & ST Invst.
$15.75B
Total Debt
$3.11B
WuXi Biologics (Cayman) Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$11.64B
+36.3%
Gross Profit
$5.67B
+73.5%
Gross Margin
48.71%
N/A
Market Cap
$19.03B
N/A
Market Cap/Employee
$1.51M
N/A
Employees
12,575
N/A
Net Income
$2.53B
+123.0%
EBITDA
$4.73B
+122.2%
Quarterly Fundamentals
Net Cash
$12.64B
+89.2%
Accounts Receivable
$8.90B
+43.9%
Inventory
$1.44B
-18.4%
Long Term Debt
$1.85B
-51.7%
Short Term Debt
$1.26B
+71.8%
Return on Assets
7.64%
N/A
Return on Invested Capital
11.88%
N/A
Free Cash Flow
$93.66M
-142.8%
Operating Cash Flow
$1.81B
-22.6%